Thread regarding BD (Becton Dickinson & Co.) layoffs

BD is shareholder first company - acquisitions and layoffs are now the norm.

This company is focused on boosting the stock price. For the last 5 years, they spent just over 6% of revenue on R&D. What does that tell you about the company? The industry average for biotech is 14%. They are focused on acquisitions, outsourcing, streamlining, and whatever else it takes to boost share price.

This is not sustainable in the long run.

By having layoffs for an entire six months session yearly, they have created a very nasty work environment to be at.

If you get laid off, it should be a relief as bad as it may be for the short term.

by
| 3721 views | | 9 replies (last March 19, 2018) | Reply
Post ID: @OP+RvCJTE8

9 replies (most recent on top)

The issue is that the company is focusing only on appearance, to make good impression on stakeholders. The substance is non existing. Pretending to do what is right, and actually doing the opposite. Pretending to do innovation, and cutting R&D. Pretending to value employees and firing good employees with 20 or more years of experience. Pretending to strive for customer centricity and not allocate resources to provide even basic service. Disgusting. When the market will start to realize they will simply sell one division. And then keep doing what is wrong.

by
| | Reply
Post ID: @Lgki+RvCJTE8

I expect Henry Becton is rolling in his grave as well.

by
| | Reply
Post ID: @Hege+RvCJTE8

Maybe BD shareholders should have sh---canned Vincent Forlenza and made Tim Ring CEO. He knew how to run a company. All we at Bard heard about was how our companies had the same philosophies and values. How this was going to be good for bard. Not even close. Charles Russell Bard must be rolling over in his grave.

by
| | Reply
Post ID: @Hngs+RvCJTE8

Working at BD is becoming a joke. The mentality for many is why bother to work hard when you known you'll be layoff any day. There's no innovation at the company nor vision from upper managment. All they do is cut cost for short term saving which isn't' sustainable long term.

by
| | Reply
Post ID: @Hzpc+RvCJTE8

Not all layoffs are the same. In this case they have recently acquired two large companies. There is a lot of duplication of duties. In this case I am sure Wall Street is looking for them to shed a lot of overhead and they will be rewarded with a higher stock price.

by
| | Reply
Post ID: @Aoiu+RvCJTE8

You have really no clue how stock market and investments work... Do you think layoffs are representation of healthy stable company and stock is going to go up because of it? You better sell those stocks and invest in some training.

by
| | Reply
Post ID: @vakk+RvCJTE8

I got canned a while back. But, I own a lot of BD stock... so, if ditching more people makes the stock go up, heck yeah!

by
| | Reply
Post ID: @iawv+RvCJTE8

So true. Here in San Diego, the future looks bleak. It appears certain the Infusion group will be targeted for more reduction as BD is staffing up in Ireland after the purchase of another small private infusion company in Israel. Something has to give. It will likely be more heads on the guillotine.

On the dispensing side, all the devices are now commodities. The vintage chart looks empty looking forward. BD isn't going to put money into R&D and new products as they keep proving over and over.

It's likely one of the buildings will be vacated and half the staff laid off by the end of the year.

BD's focus is quick money not R&D and a long term plan for success and growth at the core.

by
| | Reply
Post ID: @9bbs+RvCJTE8

This all reminds me of Valeant Pharmaceuticals and their model of cutting R&D budget, focusing on acquisitions and jacking up prices since they gained market monopoly... we all know how it ended up for Valeant.

by
| | Reply
Post ID: @5kec+RvCJTE8

Post a reply

: